Scientists working with MMV will screen 500,000 compounds for activity against Plasmodium falciparum, the most lethal of malaria parasites. Any leads identified will be progressed through AstraZeneca’s R&D facility in Bangalore, India.
MMV is currently managing a portfolio of 60 antimalarial projects in partnership with over 130 pharmaceutical, academic, and endemic-country partners in 44 countries. MMV has also launched its first product, a sweet-tasting, pediatric formulation. Two other artemisinin combination therapies, Eurartesim and Pyramax, have been submitted to the European Medicines Agency for regulatory approval. Seven further potential medicines are in clinical development.